ArticleDiscover oncology2025
Prognostic value of LncRNA DLGAP1-AS2 in bladder cancer and its regulatory effect on tumor progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
- Integrative analysis identifies a glycosylation-related lncRNA signature associated with prognosis in kidney renal clear cell carcinoma.Translational andrology and urology · 2026Article
- LncRNA ACTA2-AS1 acts as a bladder cancer prognostic biomarker and blocks malignant advance via miR-148b-3p/DNAJB4.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBladder cancer (BLCA) represents one of the most prevalent malignant neoplasms within the urinary system, and its incidence is progressively rising annually in China.
objectivesThis research investigated the clinical significance of DLGAP1-AS2, and examined its potential mechanisms in modulating the behavior of BLCA cells.
methodsThis study collected cancerous and normal tissue samples from 86 BLCA patients. qPCR was employed to assess DLGAP1-AS2 and miR-451a expression. Chi-square test was utilized to analyze the correlation between DLGAP1-AS2 and clinical parameters. Cox model and Kaplan-Meier analysis were conducted to evaluate the association between DLGAP1-AS2 and the prognosis of BLCA patients. Furthermore, DLGAP1-AS2 was silenced, both independently and jointly with miR-451a, in BLCA cell lines. CCK-8 assay assessed cell proliferation, and the Transwell assay evaluated cell migration and invasion capabilities.
resultsDLGAP1-AS2 was elevated in BLCA tissues and exhibited a correlation with both smoking history and pathological features in BLCA patients. DLGAP1-AS2 was identified as a prognostic risk factor, wherein patients exhibiting low expression had a more favorable prognosis. DLGAP1-AS2 was up-regulated in BLCA cells, and its silencing led to a reduction in the proliferation, migration, and invasion of BLCA cells. Conversely, miR-451a was down-regulated in BLCA tissues and cells, and it demonstrated a negative regulatory interaction with DLGAP1-AS2. The concurrent silencing of DLGAP1-AS2 and miR-451a effectively restored the biological behaviors of BLCA cells.
conclusionDLGAP1-AS2 is a potential biomarker for evaluating the severity of BLCA and for predicting clinical prognosis. DLGAP1-AS2 regulates the malignant progression of BLCA via miR-451a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.